nevirapine has been researched along with Hyperlipidemias in 9 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
Hyperlipidemias: Conditions with excess LIPIDS in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "All HIV-infected patients receiving a stable PI/r-based antiretroviral regimen, with persistently suppressed viremia, naïve to non-nucleoside analogues and to integrase strand transfer inhibitors, with mixed hyperlipidaemia, and who underwent a switch from PI/r to nevirapine (Group A) or raltegravir (Group B) or who started rosuvastatin at 10 mg daily (group C) with unchanged antiretroviral regimen were enrolled into the study." | 3.85 | Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study). ( Bon, I; Borderi, M; Bussini, L; Calza, L; Colangeli, V; Magistrelli, E; Re, MC; Viale, P, 2017) |
| "Limited information is currently available on the metabolic profile of nevirapine in pregnancy." | 3.75 | Plasma lipid profile in pregnant women with HIV receiving nevirapine. ( Anzidei, G; Dalzero, S; Floridia, M; Guaraldi, G; Guerra, B; Meloni, AM; Molinari, A; Pinnetti, C; Ravizza, M; Tamburrini, E; Tibaldi, C; Vimercati, A, 2009) |
| "PI substitution with nevirapine improved lipid profile in our patients, although this strategy did not show significant changes in body fat or lipodystrophy." | 3.74 | Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children. ( Amador, JT; Conejo, PR; Fontelos, PM; Gomez, ML; Gonzalez-Tome, MI; Peña, MJ, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calza, L | 2 |
| Magistrelli, E | 1 |
| Colangeli, V | 2 |
| Borderi, M | 1 |
| Bussini, L | 1 |
| Bon, I | 1 |
| Re, MC | 1 |
| Viale, P | 1 |
| Gonzalez-Tome, MI | 1 |
| Amador, JT | 1 |
| Peña, MJ | 1 |
| Gomez, ML | 1 |
| Conejo, PR | 1 |
| Fontelos, PM | 1 |
| Floridia, M | 1 |
| Tamburrini, E | 1 |
| Anzidei, G | 1 |
| Tibaldi, C | 1 |
| Guaraldi, G | 1 |
| Guerra, B | 1 |
| Meloni, AM | 1 |
| Vimercati, A | 1 |
| Molinari, A | 1 |
| Pinnetti, C | 1 |
| Dalzero, S | 1 |
| Ravizza, M | 1 |
| Moyle, GJ | 1 |
| Manfredi, R | 1 |
| Tampellini, L | 1 |
| Sebastiani, T | 1 |
| Pocaterra, D | 1 |
| Chiodo, F | 1 |
| Kumar, PN | 1 |
| Rodriguez-French, A | 1 |
| Thompson, MA | 1 |
| Tashima, KT | 1 |
| Averitt, D | 1 |
| Wannamaker, PG | 1 |
| Williams, VC | 1 |
| Shaefer, MS | 1 |
| Pakes, GE | 1 |
| Pappa, KA | 1 |
| Dieleman, JP | 1 |
| Hillebrand-Haverkort, ME | 1 |
| van der Ende, ME | 1 |
| Sturkenboom, MC | 1 |
| Lange, JM | 1 |
| Stricker, BH | 1 |
| Martínez, E | 1 |
| Gatell, JM | 1 |
1 review available for nevirapine and Hyperlipidemias
| Article | Year |
|---|---|
NNRTI choice: has 2NN changed our practice?
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Humans; Hyperlipidemias; Nevirapine; Oxazines | 2003 |
2 trials available for nevirapine and Hyperlipidemias
| Article | Year |
|---|---|
Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Bezafibrate; C | 2005 |
A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black or African American; CD4 Lymphocyte Co | 2006 |
6 other studies available for nevirapine and Hyperlipidemias
| Article | Year |
|---|---|
Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).
Topics: Adult; Anti-HIV Agents; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Cholesterol | 2017 |
Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children.
Topics: Absorptiometry, Photon; Adipose Tissue; Adolescent; Antiretroviral Therapy, Highly Active; CD4 Lymph | 2008 |
Plasma lipid profile in pregnant women with HIV receiving nevirapine.
Topics: Adolescent; Adult; Anti-HIV Agents; Cholesterol; Drug Therapy, Combination; Female; HIV Infections; | 2009 |
Safe substitution for efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; HIV Infectio | 2004 |
[Lipodystrophy and 'buffalo hump' during treatment with HIV protease inhibitors].
Topics: Adult; Cardiovascular Diseases; CD4 Lymphocyte Count; Diabetes Mellitus, Type 2; Drug Therapy, Combi | 1998 |
[Lipodystrophy and antiretroviral agents].
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Prote | 1999 |